8-K: Ovid Therapeutics Announces Business Update and Second Quarter 2024 Financial Results, Appoints New Chief Development Officer

Ovid Therapeutics reported its second quarter 2024 financial results, appointed a new Chief Development Officer, and streamlined operations to focus on key clinical programs.

Summary

• Ovid Therapeutics announced its second quarter 2024 financial results, highlighting a net income of $8.5 million, compared to a net loss of $12.4 million in the same period last year.
• The company appointed Dr. Amanda Banks as Chief Development Officer and expanded its Scientific Advisory Board.
• Ovid reduced its workforce by 43% to streamline operations and focus on priority clinical programs, incurring $3.4 million in restructuring costs.
• The company has paused the intravenous (IV) OV329 program to focus on the oral formulation and other key programs.
• Ovid's cash and marketable securities totaled $77.0 million as of June 30, 2024, expected to support operations through late H1 2026.
• The company anticipates achieving five clinical and regulatory milestones by late H1 2026.
• Revenue from royalty agreements was $169,000 for the second quarter of 2024, compared to $75,000 in the same period in 2023.
• Research and development expenses increased to $12.6 million, up from $6.0 million in the same period last year, due to pipeline advancements.
• The company expects to complete a Phase 1 multiple ascending dose (MAD) study of OV329 in H2 2024 and present ocular accumulation data in September 2024.
• Ovid intends to submit an application to study an IV formulation of OV350 in healthy human volunteers in H2 2024.

Sentiment

Score: 7

Explanation: The document shows a positive shift in financial performance with a move to net income, but also includes significant restructuring and program prioritization, which introduces some uncertainty. The company's strong cash position and pipeline advancements are positive indicators.

Positives

• Ovid achieved a net income of $8.5 million in Q2 2024, a significant turnaround from a net loss of $12.4 million in the same period last year.
• The company has a strong cash position of $77.0 million, expected to fund operations through late H1 2026.
• Ovid is advancing key pipeline programs, including OV888/GV101, OV329, and OV350.
• The appointment of Dr. Amanda Banks as Chief Development Officer and the expansion of the Scientific Advisory Board are expected to enhance clinical strategy and execution.
• The company is on track to initiate a Phase 2 proof-of-concept program for OV888/GV101 in H2 2024.
• Ovid is exploring partnerships and co-development opportunities for select programs.

Negatives

• Ovid reduced its workforce by 43%, incurring $3.4 million in restructuring costs.
• The company paused the intravenous (IV) OV329 program, which may impact development timelines.
• Research and development expenses increased significantly to $12.6 million in Q2 2024, up from $6.0 million in Q2 2023.
• The company incurred $3.4 million in one-time costs related to organizational restructuring.

Risks

• The company faces risks related to achieving projected cost savings from the restructuring.
• There are uncertainties inherent in the preclinical and clinical development and regulatory approval processes.
• Ovid may not be able to realize the intended benefits of its technology or business strategy.
• The company may not be able to identify business development targets or strategic partners, or enter into strategic transactions on favorable terms.
• The success of the pipeline programs is subject to clinical trial outcomes and regulatory approvals.

Future Outlook

Ovid expects its cash runway to support operations and clinical development through late H1 2026, during which time it plans to achieve five clinical and regulatory milestones. The company will also explore partnerships and co-development opportunities for select programs.

Management Comments

• Following Takeda's unexpected Phase 3 results for soticlestat, we moved rapidly to focus our resources to preserve capital.
• This approach included restructuring the organization and initiating ongoing program prioritization efforts to support the achievement of meaningful clinical and regulatory milestones within our financial plan.
• We are thrilled that our current pipeline remains on track to deliver anticipated results.
• To further our strategic objectives, we welcomed Dr. Amanda Banks as our Chief Development Officer.
• Her expertise, along with the expanded Scientific Advisory Board, will enhance our ability to capitalize on therapeutic opportunities and prioritize efforts where we can most benefit patients.

Industry Context

This announcement comes in the context of a challenging period for biotech companies, with many facing pressure to streamline operations and focus on core programs. Ovid's restructuring and pipeline prioritization efforts are consistent with this trend. The company's focus on rare epilepsies and brain conditions aligns with the growing interest in developing treatments for underserved patient populations.

Comparison to Industry Standards

• Ovid's cash position of $77.0 million is relatively strong for a company of its size and stage, providing a runway through late H1 2026, which is a positive sign compared to many other biotech companies that are facing funding challenges.
• The 43% workforce reduction is a significant move, reflecting the need to conserve capital and focus on core programs, which is a common strategy in the current biotech environment. Companies like Sage Therapeutics and Biogen have also undertaken similar restructuring efforts recently.
• The increase in R&D expenses to $12.6 million indicates a commitment to advancing its pipeline, which is crucial for a biotech company. However, this increase needs to be balanced with the need to manage cash burn effectively. Companies like Neurocrine Biosciences and Global Blood Therapeutics have also seen increases in R&D spending as they advance their clinical programs.
• The net income of $8.5 million is largely due to a fair value adjustment to the royalty monetization liability, which is not a recurring operational profit. This highlights the importance of focusing on operational performance and pipeline progress. Companies like Vertex Pharmaceuticals and Regeneron have demonstrated consistent operational profitability through successful commercialization of their products.

Management Changes

Stakeholder Impact

• Shareholders may view the improved financial results and pipeline progress positively, but the restructuring and workforce reduction may cause concern.
• Employees have been impacted by the 43% workforce reduction.
• Patients may benefit from the advancement of Ovid's pipeline programs, but the pausing of the OV329 IV program may delay potential treatments.
• Partners and suppliers may be affected by the company's restructuring and prioritization efforts.

Next Steps

• Ovid will initiate a Phase 2 proof-of-concept program for OV888/GV101 in H2 2024.
• The company will complete a Phase 1 multiple ascending dose (MAD) study of OV329 in H2 2024.
• Ovid will present ocular accumulation data for OV329 at the Epilepsy Foundation Pipeline Conference in September 2024.
• Ovid intends to submit an application to study an IV formulation of OV350 in healthy human volunteers in H2 2024.
• The company will explore partnerships and co-development opportunities for select programs.

Key Dates

Keywords

Ovid Therapeutics, Clinical Trials, Biopharmaceutical, Rare Epilepsies, Neurology, OV888/GV101, OV329, OV350, Soticlestat, Financial Results, Drug Development, Phase 2, Phase 1, KCC2, ROCK2